Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ) has shared an update.
Charmacy Pharmaceutical Co., Ltd. has announced the renewal of its continuing connected transactions through a new framework loan agreement with Jiangyao, a controlling shareholder of the company. This agreement, effective from January 1, 2026, for a term of three years, allows Jiangyao to provide a loan facility to Charmacy, subject to statutory approval. The new agreement is considered a continuing connected transaction under the listing rules, requiring shareholder approval and annual review. An independent board committee and financial adviser have been appointed to assess the fairness and reasonableness of the agreement.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a pharmaceutical company based in China. It operates in the healthcare industry, focusing on pharmaceutical products and services.
Average Trading Volume: 47,613
Technical Sentiment Signal: Sell
Current Market Cap: HK$584.3M
For an in-depth examination of 2289 stock, go to TipRanks’ Overview page.